Standby emergency treatment of malaria in travelers: Experience to date and new developments

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 5, 2012, Pages 537-546

  Schlagenhauf, Patricia ^a   Petersen, Eskild ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

counterfeit drugs; malaria; standby emergency treatment; travel

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CLINDAMYCIN; DIHYDROARTEMISININ PLUS PIPERAQUINE; DOXYCYCLINE; MEFLOQUINE; PRIMAQUINE; QUININE;

AFRICA; ASIA; CHEMOPROPHYLAXIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE SURVEILLANCE; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG QUALITY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; EMERGENCY TREATMENT; ENDEMIC DISEASE; HEALTH CARE POLICY; HUMAN; INFECTION RISK; INSECT BITE; MALARIA; MOSQUITO; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PLASMODIUM OVALE MALARIA; PLASMODIUM VIVAX MALARIA; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; STANDBY EMERGENCY TREATMENT; SYMPTOM; TRAVEL; WORLD HEALTH ORGANIZATION;

ANTIMALARIALS; ARTEMISININS; ATOVAQUONE; CHLOROQUINE; DIAGNOSTIC TESTS, ROUTINE; DRUG COMBINATIONS; EMERGENCY TREATMENT; ETHANOLAMINES; FEMALE; FLUORENES; GEOGRAPHY; GUIDELINES AS TOPIC; HEALTH POLICY; HUMANS; MALARIA; PLASMODIUM; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PROGUANIL; SENSITIVITY AND SPECIFICITY; TRAVEL; TRAVEL MEDICINE;

EID: 84862516818     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.42     Document Type: Review

References (51)

1. Schlagenhauf P, Petersen E. Malaria chemoprophylaxis: Strategies for risk groups. Clin. Microbiol. Rev. 21(3), 466-472 (2008).
2. Jelinek T, Schulte C, Behrens R et al. Imported Falciparum malaria in Europe: Sentinel surveillance data from the European network on surveillance of imported infectious diseases. Clin. Infect. Dis. 34(5), 572-576 (2002).
3. Weber R, Schlagenhauf P, Amsler L, Steffen R. Knowledge, attitudes and practices of business travelers regarding malaria risk and prevention. J. Travel Med. 10(4), 219-224 (2003).
4. Phillips-Howard PA, Bradley DJ, Blaze M, Hurn M. Malaria in Britain: 1977-86. Br. Med. J. (Clin. Res. Ed.) 296(6617), 245-248 (1988).
5. Christen D, Steffen R, Schlagenhauf P. Deaths caused by malaria in Switzerland 1988-2002. Am. J. Trop. Med. Hyg. 75(6), 1188-1194 (2006).
6. Jelinek T, Schade Larsen C, Siikamäki H et al. European cluster of falciparum malaria from Gambia. Euro. Surveill. 13(51), pii (2008).
7. Mali S, Kachur SP, Arguin PM; Division of Parasitic Diseases and Malaria, Center for Global Health. Malaria surveillance -USA, 2010. MMWR. Surveill. Summ. 61(2), 1-17 (2012).
8. Legros F, Bouchaud O, Ancelle T et al.; for the French National Reference Centers for Imported and Autochthonous Malaria Epidemiology and Chemosensitivity Network. Risk factors for imported fatal Plasmodium falciparum malaria, France, 1996-2003. Emerging Infect. Dis. 13(6), 883-888 (2007).
9. Seringe E, Thellier M, Fontanet A et al.; French National Reference Center for Imported Malaria Study Group. Severe imported Plasmodium falciparum malaria, France, 1996-2003. Emerging Infect. Dis. 17(5), 807-813 (2011).
10. Kain KC, MacPherson DW, Kelton T, Keystone JS, Mendelson J, MacLean JD. Malaria deaths in visitors to Canada and in Canadian travellers: A case series. CMAJ 164(5), 654-659 (2001).
11. Newman RD, Parise ME, Barber AM, Steketee RW. Malaria-related deaths among US travelers, 1963-2001. Ann. Intern. Med. 141(7), 547-555 (2004).
12. Mühlberger N, Jelinek T, Behrens RH et al. TropNetEuropSurveillance importierter Infektionen in Deutschland Surveillance Networks. Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: Observations from TropNetEurop and SIMPID Surveillance Data. Clin. Infect. Dis. 36(8), 990-995 (2003).
13. Krause G, Schöneberg I, Altmann D, Stark K. Chemoprophylaxis and malaria death rates. Emerging Infect. Dis. 12(3), 447-451 (2006).
14. Chen LH, Wilson ME, Schlagenhauf P. Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA 297(20), 2251-2263 (2007).
15. Schlagenhauf P, Tschopp A, Johnson R et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: Multicentre, randomised, double blind, four arm study. BMJ 327(7423), 1078 (2003).
16. Steffen R, Fuchs E, Schildknecht J et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 341(8856), 1299-1303 (1993).
17. Askling HH, Nilsson J, Tegnell A, Janzon R, Ekdahl K. Malaria risk in travelers. Emerging Infect. Dis. 11(3), 436-441 (2005).
18. Schmid S, Chiodini P, Legros F et al. The risk of malaria in travelers to India. J. Travel Med. 16(3), 194-199 (2009).
19. Behrens RH, Carroll B, Hellgren U et al. The incidence of malaria in travellers to south-east Asia: Is local malaria transmission a useful risk indicator? Malar. J. 9, 266 (2010).
20. Schlagenhauf P. Stand-by emergency treatment of malaria by travellers. In: Travelers' Malaria (2nd Edition). Schlagenhauf-Lawlor P (Ed.). BC Decker, ON, Canada, 316-322 (2008).
21. Schlagenhauf P, Steffen R, Tschopp A et al. Behavioural aspects of travellers in their use of malaria presumptive treatment. Bull. World Health Organ. 73(2), 215-221 (1995).
22. Bhattarai A, Ali AS, Kachur SP et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med. 4(11), e309 (2007).
23. Poravuth Y, Socheat D, Rueangweerayut R et al. Pyronaridine-Artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: A randomized, double-blind, non-inferiority trial. PLoS ONE 6(1), e14501 (2011).
24. Phyo AP, Lwin KM, Price RN et al. Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: A randomized controlled trial. Clin. Infect. Dis. 53(10), 977-984 (2011).
25. Weinke T, Trautmann M, Held T et al. Neuropsychiatric side effects after the use of mefloquine. Am. J. Trop. Med. Hyg. 45(1), 86-91 (1991).
26. Steketee RW, Wirima JJ, Slutsker L, Khoromana CO, Heymann DL, Breman JG. Malaria treatment and prevention in pregnancy: Indications for use and adverse events associated with use of chloroquine or mefloquine. Am. J. Trop. Med. Hyg. 55(Suppl. 1), 50-56 (1996).
27. Schlagenhauf P, Blumentals W, Suter P et al. Pregnancy and fetal outcomes after exposure to mefloquine in the perinatal and pregnancy periods. Clin. Infect. Dis. doi:10.1093/cid/cis215 (2012) (Epub ahead of print).
28. McGready R, Lee S, Wiladphaingern J et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: A population-based study. Lancet Infect. Dis. 12(5), 388-396 (2011)
29. Morris CA, Onyamboko MA, Capparelli E et al. Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria. Malar. J. 10, 114 (2011).
30. Gargano N, Cenci F, Bassat Q. Antimalarial efficacy of piperaquine-based antimalarial combination therapies: Facts and uncertainties. Trop. Med. Int. Health doi:10.1111/j.1365-3156.2011.02855.x (2011) (Epub ahead of print).
31. Yavo W, Faye B, Kuete T et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malar. J. 10, 198 (2011).
32. Mayxay M, Keomany S, Khanthavong M et al. A Phase III, randomized, noninferiority trial to assess the efficacy and safety of dihydroartemisinin- piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. Am. J. Trop. Med. Hyg. 83(6), 1221-1229 (2010).
33. Nothdurft HD, Jelinek T, Pechel SM et al. Stand-by treatment of suspected malaria in travellers. Trop. Med. Parasitol. 46(3), 161-163 (1995).
34. Newton PN, Green MD, Fernández FM, Day NP, White NJ. Counterfeit antiinfective drugs. Lancet Infect. Dis. 6(9), 602-613 (2006).
35. Newton PN, Green MD, Fernandez F. Counterfeit artemisinin derivatives and Africa: Update from authors. PLoS Med. 4(3), e139 (2007).
36. Newton PN. Chapter 20. In: Travelers' Malaria (2nd Edition). Schlagenhauf-Lawlor P (Ed.). BC Decker, ON, Canada, 331-342 (2008).
37. Uguen C, Rabodonirina M, De Pina JJ et al. ParaSight-F rapid manual diagnostic test of Plasmodium falciparum infection. Bull. World Health Organ. 73(5), 643-649 (1995).
38. Funk M, Schlagenhauf P, Tschopp A, Steffen R. MalaQuick versus ParaSight F as a diagnostic aid in travellers' malaria. Trans. R. Soc. Trop. Med. Hyg. 93(3), 268-272 (1999).
39. Petersen E, Marbiah NT, New L, Gottschau A. Comparison of two methods for enumerating malaria parasites in thick blood films. Am. J. Trop. Med. Hyg. 55(5), 485-489 (1996).
40. Gama BE, Silva-Pires Fdo E, Lopes MN et al. Real-time PCR versus conventional PCR for malaria parasite detection in low-grade parasitemia. Exp. Parasitol. 116(4), 427-432 (2007).
41. Grobusch MP, Hänscheid T, Göbels K et al. Sensitivity of P. vivax rapid antigen detection tests and possible implications for self-diagnostic use. Travel Med. Infect. Dis. 1(2), 119-122 (2003).
42. Jelinek T. Malaria self-testing by travellers: Opportunities and limitations. Travel Med. Infect. Dis. 2(3-4), 143-148 (2004).
43. Berg J, Breederveld D, Roukens AH et al. Knowledge, attitudes, and practices toward malaria risk and prevention among frequent business travelers of a major oil and gas company. J. Travel Med. 18(6), 395-401 (2011).
44. Luchavez J, Baker J, Alcantara S et al. Laboratory demonstration of a prozone-like effect in HRP2-detecting malaria rapid diagnostic tests: Implications for clinical management. Malar. J. 10, 286 (2011).
45. Gillet P, Scheirlinck A, Stokx J et al. Prozone in malaria rapid diagnostics tests: How many cases are missed? Malar. J. 10, 166 (2011).
46. Koita OA, Doumbo OK, Ouattara A et al. False-negative rapid diagnostic tests for malaria and deletion of the histidinerich repeat region of the hrp2 gene. Am. J. Trop. Med. Hyg. 86(2), 194-198 (2012).
47. Baker J, Gatton ML, Peters J, Ho MF, McCarthy JS, Cheng Q. Transcription and expression of Plasmodium falciparum histidine-rich proteins in different stages and strains: Implications for rapid diagnostic tests. PLoS One 6(7), e22593 (2011).
48. Chiodini PL, Bowers K, Jorgensen P et al. The heat stability of Plasmodium lactate dehydrogenase-based and histidine-rich protein 2-based malaria rapid diagnostic tests. Trans. R. Soc. Trop. Med. Hyg. 101(4), 331-337 (2007).
49. Sutherland CJ, Tanomsing N, Nolder D et al. Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. J. Infect. Dis. 201(10), 1544-1550 (2010).
50. Tordrup D, Virenfeldt J, Andersen FF, Petersen E. Variant Plasmodium ovale isolated from a patient infected in Ghana. Malar. J. 10(1), 15 (2011).
51. Hellemond JJ, Van Rutten M, Koelewijn R et al. Human Plasmodium knowlesi infection detected by rapid diagnostic tests for malaria. Emerg. Infect. Dis. 15, 1478-1480 (2009).